COMMUNIQUÉS West-GlobeNewswire

Catalyst Pharmaceuticals to Showcase Real‑World Findings in Duchenne Muscular Dystrophy and Host Vamorolone-Focused Symposium at the 2026 MDA Clinical & Scientific Conference
06/03/2026
CORAL GABLES, Fla., March 06, 2026 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing [...]
AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business and Clinical Update
06/03/2026
Phase 3 pivotal program initiation for BPL-003 in treatment-resistant depression remains on track for Q2 2026 following successful End‑of‑Phase 2 meeting with the U.S. Food and Drug Administration On-track for VLS-01 [...]
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06/03/2026
SAN DIEGO, March 06, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today [...]
PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights
06/03/2026
Enrollment remains on track in Phase 2 pivotal portion of PYNNACLE trial evaluating rezatapopt as monotherapy in platinum-resistant/refractory ovarian cancer patients with a TP53 Y220C mutation Rezatapopt granted Orphan [...]
Intended Retirement of Independent Non-executive Director and changes of composition of board committees
06/03/2026
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 06, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ” or the “Company”) (Nasdaq/AIM:HCM, HKEX:13) today announces that Professor Mok Shu Kam, Tony has [...]
Claritas iPET™ Approved by Australia TGA to Supply the Medical Software Device for Image Processing Enabling Diagnostic Quality Images from Short Scan Time and/or Low Dose PET, PET-CT/MRI Scans
06/03/2026
LONDON and SYDNEY, March 06, 2026 (GLOBE NEWSWIRE) -- Claritas NucMed Technologies Ltd (Claritas), a healthcare technology company specializing in state-of-the-art image enhancement, noise reduction, segmentation and [...]
argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline
06/03/2026
Positive results from Phase 3 ADAPT OCULUS study show VYVGART’s potential as the first targeted treatment for patients living with ocular MG Additional data from ADAPT SERON – the largest study of patients with gMG who [...]
Fagron publishes its Annual Report 2025
06/03/2026
Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 6 March 2026 7AM CET Fagron publishes its Annual Report 2025 Fagron, the leading global player in pharmaceutical compounding, today publishes its [...]
Quipt Home Medical Receives Final Order Approving Arrangement
06/03/2026
CINCINNATI, March 05, 2026 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (the “ Company ”) (NASDAQ: QIPT; TSX: QIPT)‎, a U.S. based home medical equipment provider, focused on end-to-end respiratory care, announces that [...]
Rakovina Announces Closing of $1 Million Debenture Unit Private Placement and Debt Settlement Agreements
06/03/2026
VANCOUVER, British Columbia, March 05, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV; FSE: 7JO0) (“Rakovina” or the “Company”), a biopharmaceutical company advancing innovative cancer therapies through [...]
Paingone Plus TENS Pen Featured in 2026 Consumer Report Examining FDA Clearance Status, TENS Pain Therapy Research, and Portable Pain Relief Device Verification
06/03/2026
A 2026 consumer research report examining Paingone Plus TENS pen searches, portable TENS pain relief device claims, FDA clearance status, published nerve stimulation therapy research, doctor endorsement context, and [...]
Calidi Biotherapeutics Announces Proposed Public Offering
05/03/2026
SAN DIEGO, March 05, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today [...]
Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026
05/03/2026
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT SOUTH SAN FRANCISCO, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical [...]
Galapagos Appoints Tania Philipp as Chief Human Resources Officer
05/03/2026
Seasoned Life Sciences Executive Joins Galapagos with Strong Track Record in Change Management Mechelen, Belgium; March 5, 2026, 22:01 CET — Galapagos NV (Euronext & NASDAQ: GLPG) today announced the appointment of [...]
Omada Health Reports Fourth Quarter and Full-Year 2025 Results
05/03/2026
Revenue up 58% in Fourth Quarter, 53% for Year; Member Growth of 55% for Year Achieves Positive Net Income in Fourth Quarter; Significantly Narrows Net Loss for Full Year Delivers Positive Adjusted EBITDA for Full Year [...]
Tevogen Advances Generics Strategy, Signs Letter of Intent to Evaluate Potential Acquisition of Apozeal Pharmaceutical
05/03/2026
WARREN, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ) today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent (“LoI”) [...]
Metagenomi Therapeutics Reports Business Updates and Full Year 2025 Financial Results
05/03/2026
Completed pre-IND meeting following MGX-001 preclinical data demonstrating curative FVIII activity in non-human primates (NHPs) and remains on track for global regulatory submission including investigational new drug [...]
BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting
05/03/2026
PHILADELPHIA and VANCOUVER, British Columbia, March 05, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX , BCTXL ) (TSX:BCT) (“BriaCell” or the “Company”) , a clinical-stage biotechnology company that [...]
aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update
05/03/2026
Company scheduled to meet with the FDA in mid-April 2026 to review the results of the Phase 3 EFZO-FIT™ study and determine the path forward for efzofitimod in pulmonary sarcoidosis. Phase 2 EFZO-CONNECT™ study of [...]

Pages